Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

0.64USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,170
52-wk High
$1.77
52-wk Low
$0.32

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)
No analyst recommendations are available for .

Overall

Beta: 1.75
Market Cap(Mil.): $11.85
Shares Outstanding(Mil.): 23.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

11 Dec 2017

BRIEF-RXi Pharma and Gustave Roussy have entered into a collaborative research agreement​

* RXi Pharmaceuticals Corp - ‍co, Gustave Roussy announced that they have entered into a collaborative research agreement​

13 Nov 2017

BRIEF-RXi Pharmaceuticals reports Q3 2017 financial results and recent corporate highlights

* Reports third quarter 2017 financial results and recent corporate highlights

08 Nov 2017

BRIEF-RXi Pharmaceuticals files for sale of up to 7.3 mln shares

* RXi Pharmaceuticals Corp- files for sale of up to 7.3 million shares of common stock by Lincoln Park Capital Fund Llc - SEC filing‍​ Source text: (http://bit.ly/2vQLno4) Further company coverage:

18 Aug 2017

Earnings vs. Estimates